CD8A and agammaglobulinemia: Next, SARS-CoV-2 spike (S)-specific CD4+ and CD8+ T cell responses were assessed from hypogammaglobulinemia patients (n=31) and immunocompetent HCWs (n=10) with activation induced marker (AIM) assay.